Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

54 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Measurable Residual Disease Testing Following Nonintensive Chemoimmunotherapy is Predictive of Need for Maintenance Therapy in Previously Untreated Mantle Cell Lymphoma: A Wisconsin Oncology Network Study.
Chang JE, McQuinn D, Hyun M, Kim K, Kenkre VP, Rajguru SA, Pophali PA, Endres M, Howard M, Wassenaar T, Warren RC, Mattison RJ, Wisinski KB, Fletcher CD. Chang JE, et al. Among authors: kenkre vp. Clin Lymphoma Myeloma Leuk. 2024 Oct 9:S2152-2650(24)02358-9. doi: 10.1016/j.clml.2024.09.014. Online ahead of print. Clin Lymphoma Myeloma Leuk. 2024. PMID: 39477701
Decitabine induction with myeloablative conditioning and allogeneic hematopoietic stem cell transplantation in high-risk patients with myeloid malignancies is associated with a high rate of infectious complications.
D'Angelo CR, Hall A, Woo KM, Kim K, Longo W, Hematti P, Callander N, Kenkre VP, Mattison R, Juckett M. D'Angelo CR, et al. Among authors: kenkre vp. Leuk Res. 2020 Sep;96:106419. doi: 10.1016/j.leukres.2020.106419. Epub 2020 Jul 8. Leuk Res. 2020. PMID: 32683127 Free PMC article. Clinical Trial.
TCR-α/β and CD19 depleted stem cell grafts from haploidentical donors for allogeneic transplantation in patients with relapsed lymphoma: a single-center experience.
Kenkre VP, Bradley K, Milton A, Burkholder JK, Grindle K, McMannes J, Kim K, Callander N, Juckett M, Longo W, Hematti P. Kenkre VP, et al. Leuk Lymphoma. 2023 Nov-Dec;64(11):1875-1879. doi: 10.1080/10428194.2023.2240918. Epub 2023 Aug 10. Leuk Lymphoma. 2023. PMID: 37585704 No abstract available.
Multicenter Analysis of Advanced Stage Grade 3A Follicular Lymphoma Outcomes by Frontline Treatment Regimen.
Shah NN, Szabo A, Saba R, Strelec L, Kodali D, Vaughn JL, Esan O, Yang DT, Mato AR, Kanate AS, Olteanu H, Hamadani M, Fenske TS, Kenkre VP, Svoboda J, Cashen AF, Epperla N. Shah NN, et al. Among authors: kenkre vp. Clin Lymphoma Myeloma Leuk. 2019 Feb;19(2):95-102. doi: 10.1016/j.clml.2018.11.010. Epub 2018 Nov 12. Clin Lymphoma Myeloma Leuk. 2019. PMID: 30581160
Follicular lymphoma patients with KIR2DL2 and KIR3DL1 and their ligands (HLA-C1 and HLA-Bw4) show improved outcome when receiving rituximab.
Erbe AK, Wang W, Carmichael L, Hoefges A, Grzywacz B, Reville PK, Ranheim EA, Hank JA, Kim K, Seo S, Mendonca EA, Song Y, Kenkre VP, Hong F, Gascoyne RD, Paietta E, Horning SJ, Miller JS, Kahl B, Sondel PM. Erbe AK, et al. Among authors: kenkre vp. J Immunother Cancer. 2019 Mar 12;7(1):70. doi: 10.1186/s40425-019-0538-8. J Immunother Cancer. 2019. PMID: 30871628 Free PMC article. Clinical Trial.
Burkitt lymphoma/leukemia: improving prognosis.
Kenkre VP, Stock W. Kenkre VP, et al. Clin Lymphoma Myeloma. 2009;9 Suppl 3:S231-8. doi: 10.3816/CLM.2009.s.017. Clin Lymphoma Myeloma. 2009. PMID: 19778846 Review.
[No title available]
[No authors listed] [No authors listed] PMID: 39112217
54 results